Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 66.67 mg (equivalent: lanreotide, qty 60 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 133.33 mg (equivalent: lanreotide, qty 120 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - lanreotide acetate, quantity: 100 mg (equivalent: lanreotide, qty 90 mg) - injection, solution - excipient ingredients: water for injections; glacial acetic acid - mytolac is indicated for:,- the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory,- the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours,- the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bevacizumab, quantity: 25 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate; polysorbate 20; trehalose dihydrate - metastatic colorectal cancer bevaciptin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. locally recurrent or metastatic breast cancer bevaciptin (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated (see section 5.1 clinical trials). advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc) bevaciptin (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first- line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer. advanced and/or metastatic renal cell cancer bevaciptin (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer. grade iv glioma bevaciptin (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy. epithelial ovarian, fallopian tube or primary peritoneal cancer bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first- line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors. bevaciptin (bevacizumab) in combination with topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab. cervical cancer bevaciptin (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. bevaciptin (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bevacizumab, quantity: 25 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; trehalose dihydrate; dibasic sodium phosphate; polysorbate 20 - metastatic colorectal cancer bevaciptin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. locally recurrent or metastatic breast cancer bevaciptin (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated (see section 5.1 clinical trials). advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc) bevaciptin (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first- line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer. advanced and/or metastatic renal cell cancer bevaciptin (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer. grade iv glioma bevaciptin (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy. epithelial ovarian, fallopian tube or primary peritoneal cancer bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first- line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors. bevaciptin (bevacizumab) in combination with topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab. cervical cancer bevaciptin (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. bevaciptin (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - ? hypoxia of any cause. ? as diluent for gaseous and volatile anaesthetic agents.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

upl australia pty ltd - chlorpyrifos; chlorpyrifos; liquid hydrocarbon; liquid hydrocarbon; liquid hydrocarbon - emulsifiable concentrate - chlorpyrifos organophosphorus active 500.0 g/l; chlorpyrifos organophosphorus active 500.0 g/l; liquid hydrocarbon solvent other 470.0 g/l; liquid hydrocarbon solvent other 490.0 g/l; liquid hydrocarbon solvent other 480.0 g/l - insecticide - apple | asparagus | avocado | banana | barley | bean | beetroot | broad bean | broccoli | brussels sprouts | cabbage | canola | - african black beetle | ant | argentine ant | argentine stem weevil | australian plague locust | avocado leafroller | banana scab moth | banana weevil borer | black beetle | blackheaded pasture cockchafer | blue oat or pea mite | bluegreen aphid | brown pasture looper | brown planthopper | cabbage aphid | cabbage cluster caterpillar | cabbage moth | cabbage white butterfly | california red scale | cluster caterpillar | cockroach | cockroach infestation - heavy/residual | cockroach infestation - light | common armyworm | common armyworm - mythimna convecta | common cutworm - agrotis infusa | common cutworm - agrotis spp. | common mango scale | corbie | corn aphid | corn earworm | cotton aphid | cotton flea beetle | cricket | cutworm | cutworm - agrotis spp. | european earwig | false wireworm | field cricket | flea - outdoors only | funnel ant | grapevine moth | grapevine scale | green peach aphid | green vegetable bug | hairy caterpillar | helicoverpa punctigera | helicoverpa spp. | hide or skin beetle | ivy le

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agro-alliance (australia) pty ltd - glyphosate present as the mono-ammonium salt - water soluble granules - glyphosate present as the mono-ammonium salt glycine active 700.0 g/kg - herbicide - agricultural/farm buildings | almond | annual grass weed - seed set control | avocado | banana | blueberry | buildings - around - african lovegrass | african turnip weed | amaranth or amaranthus | amsinckia | annual phalaris | annual ryegrass | annual weeds | artichoke thistle | australian bluebell - w. gracilis | bamboo | barley grass | barnyard or water grass | bathurst burr | bent grass - agrostis spp. | bitou bush or boneseed | blackberry | bladder ketmia | blady grass | boggabri weed | boxthorn | bracken | brome grass | burr medic | calomba daisy | caltrop or yellow vine | camel or afghan melon | canary grass | capeweed | carpet grass | cat's ear or flatweed | chickweed | chinese scrub | cobbler's pegs | cocksfoot | columbus grass - seedling | couch | cudweed | cumbungi | deadnettle | dock | dock - seedling | english couch or rope twitch | erodium, crowfoot or storksbill | eucalyptus - seedling up to 2 m tall | fumitory | furze or gorse | giant or black pigweed | glyceria or reed sweet grass | gooseberry | ground cherry - physalis angulata | groundsel bush | guinea grass | hawthorn | hedge or wild mustard | hoary cress or whiteweed

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - paraquat present as paraquat dichloride; amitrole - aqueous concentrate - paraquat present as paraquat dichloride pyridine-bipyridyl active 250.0 g/l; amitrole triazole active 10.0 g/l - herbicide - aid to cultivation - weed control | annual clover - selective weed control | firebreak weed control | hay freezing (pastures) | - annual grass weed | annual weed control | barley grass | broadleaf weeds | destroy seed head - spray top/graze | grass weed | pre-harvest weed control | reduce vegetative growth | retention of protein in standing dry fee | saffron thistle | wild oat | annual grasses | broadleaf grass | control excess vine growth | control excess.veg.growth | false star thistle | reduce fire hazard/ weed growt | residual weed control